Discussion

Started 17 October 2018

Abohassan Farhang Sardrodi

University of Mohaghegh Ardabili

What subject do you suggest for writing a systematic review in aromatherapy?

I want a subject for writing a systematic review in aromatherapy.

My idea is on headache, but if you suggest a subject we can do this together.

sincerely yours

Abohassan Farhang S.

Systematic Reviews

Abohassan Farhang Sardrodi

University of Mohaghegh Ardabili

thank you, but I think after research, if I write a systematic review on aromatherapeutic properties of a plant is better than a malady. like Rosemary or Thyme or ...

Do you have offers?

Abohassan.

Francisco Javier Gala

Universidad de Cádiz

Gianluigi Segalerba

University of Coimbra

Aristidis Matsoukis

Agricultural University of Athens

Daniel Lüdecke

University Medical Center Hamburg - Eppendorf

Nepal Eye Hospital

Christopher A Smith

York Hospital

Abohassan,

Aromatherapy has been touted to relieve many maladies. My suggestion is to pick two or three that interest you and search the literature to evaluate the volume of literature available. There are many studies related to treatment of nausea (for example), although the N is often small and the quality is often low. A review containing a small number of low quality studies would not yield much value for the effort you will need to put forward. IMHO.

Have a Blessed Day!

Christopher

Jilin University

efficacy and safty for insomnia or anxiety disorders 。。。。

1 Recommendation

Jonathan H Smith

AbbVie

Hi headache (migraine more specifically) is reasonable. There are 3 clinical trials that come to mind and there is not a previously published review. Best Jonathan

1 Recommendation

Abohassan Farhang Sardrodi

University of Mohaghegh Ardabili

thank you, but I think after research, if I write a systematic review on aromatherapeutic properties of a plant is better than a malady. like Rosemary or Thyme or ...

Do you have offers?

Abohassan.

Why tertiary-headache center researchers must do a lot of soul-searching before they embark on the next Industry-sponsored Randomized Clinical Trial?

Asked 20 November 2018

Vinod Kumar Gupta

HALL OF SHAME

By the 1920s, medical researchers had become heroes to many Americans (Lederer, 1995).

By the 21 st Century, performers of Randomized Controlled Trials have become heroes in their own eyes, while the educated population has begun to take a guarded approach to medical fishing expeditions.

The time is near, very near, I predict, that participants in RCTs will be hard to find.

Thoughtless and mindless headache research that I have been following from 1974 will, I repeat, will be (not may or might) the greatest contributor to failure to find human guinea pigs after 2030 or earlier.

Two factors propel patients into RCTs: faith in their doctors and altruism. Once a person is cheated, or feels cheated -- not even a thank-you for participation, no provision for receiving data, or follow-up reports, or post-publication singeing critiques -- well, the writing is on the wall. I am not alone in this perception. Alturism can evaporate far faster than any other positive human attribute.

My article published in 2010 (Expert Rev. Neurother. 10(9), 1409-1422, OPEN ACCESS and attached along with) is a must-read for all RCT participants who look with hope and trust to their medical doctors, and, for all empathic medical doctors of succeeding generations for all time who aspire some day to be participants in RCTs.

As this thread evolves, I will add one head-hanging RCT each time. If the trialist(s) has/have not used the same medication for themselves or for her/his loved one or for one as knowledgeable as a Cardiologist/Neurologist/Physician or the trial falls far short of overarching robust and defensible LOGIC, it enters the <HALL of SHAME>

Most of such trials originate in the US of America, with Cardiologists/Neurologists from other countries being sucked into the vortex.

No one controls these trials; the FDA encourages such trials over hapless patients. As America is undoubtedly the most litigious society on Earth, such trialists are playing with fire, just like flunarizine is not use in the US because of its rare potential to cause drug-induced Parkinsonism. Besides legal remedy, the US of A is infamous for a more rapid expression of disgust and settling of scores.

Someone has to stand up for the discipline of Medicine and Neurology.

The single undisputed and non-controversial pharmacological absolute that challenges the putative cortical hyperexcitability-glutamate-migraine nexus is the established therapeutic role of TCAs. Amitriptyline is lipophilic; crosses BBB readily. Prevents migraine effectively (Jackson et al. 2010; Couch 2011). May cause serotonin syndrome (Sternbach 1991; Sporer 1995; Gillman 2010; Boyer and Shannon 2005). Despite promoting sleep and improving depression, can induce convulsive seizure in overdose (Paksu et al. 2014) and lead to mania when used in combination with MAO-inhibitors (de la Fuente et al. 1986) or induced by withdrawal (Dilsaver and Greden 1986) indicating a well-modulated cortical hyperexcitability. Combination of propranolol and amitriptyline, paradoxically, works very well for migraine prophylaxis. Protriptyline, nortriptyline, and venlafaxine are other antidepressants that prevent migraine (Silberstein 2015).

Since ethics is forever an unending debate, I have presented a cast-iron vision of ethical practice in medicine (Gupta, 1999). The antithesis of ethics can be found in "Death of a Salesman" - Arthur Miller, 1949 (1915-2005). When doctors turn salespersons, unethical trails result. As a result, truth dissociated itself from such endeavours. Motive is more important than methods (Denis P. Burkitt).

Attitudes are more important than abilities.

Motives are more important than methods.

Character is more important than cleverness.

Perseverance is more important than power.

And the heart takes precedence over the head (Burkitt, 1992, placed

on page 72, Adaptive Mechanisms of Migraine. Breaking the Migraine

Code. Gupta VK. Nova Science, New York, NY, 2009)

History is unforgiving, and, hindsight enjoys perfect 20/20 vision. Just like pneumoencephalography as a therapy for benign cough-induced headache has become obsolete in the late 20th century (see Gupta VK, Headache. 2005; May;45(5):612-4.; Gupta VK. Med Hypotheses. 2004;62(1):45-8.; Gupta VK.

Int J Clin Pract. 2007 Feb;61(2):345-8), such trials will remain etched in time as medical blunders that simply eased through time.

Till the end of the second decade of the 21st Century, migraine is a classical example of how NOT to carry out research.

This time I attach RCTs on glutamate and migraine:

Cephalalgia. 2014 Feb;34(2):103-13. doi: 10.1177/0333102413499648. Epub 2013 Aug 20.

Randomized, multicenter trial to assess the efficacy, safety and tolerability of a single dose of a novel AMPA receptor antagonist BGG492 for the treatment of acute migraine attacks.

Gomez-Mancilla B1, Brand R, Jürgens TP, Göbel H, Sommer C, Straube A, Evers S, Sommer M, Campos V, Kalkman HO, Hariry S, Pezous N, Johns D, Diener HC; BGG492 Study Group.

Waung MW, Akerman S, Wakefield M, Keywood C, Goadsby PJ. Metabotropic glutamate receptor 5: a target for migraine therapy. Ann Clin Transl Neurol 3, 560-571, 2016.

Sang CN, Ramadan NM, Wallihan RG, Chappell AS, Freitag FG, Smith TR, Silberstein SD, Johnson KW, Phebus LA, Bleakman D, Ornstein PL, Arnold B, Tepper SJ, Vandenhende F. LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine. Cephalalgia 24, 596-602, 2004.

References:

Lederer SE. Subjected to science: Human experimentation in Americas before the Second World War. Baltimore, John Hopkins University Press, 1995, pp 51-72.

Gupta VK. Does magnesium supplementation have any role in acute myocardial infarction? Cardiovasc. Drugs Ther. 1996, 10, 303-305.

Gupta, J. Medical Ethics 1996, 22, 245, 246, with response from the hen British Medical Journal Editor-in-Chief, Richard Smith and a Journalist/General Practitioner Naomi Craft, 1996, 22, 245-246 with retraction of Editorial policy (removed by BMJ from online access); comments 360-361.

New Delhi 21 Novemeber 2018

ORCiD ID: 0000-0002-6770-5916

What's the nitric oxide synthesis inhibitor's role in migrane headache?

Asked 7 March 2018

Ramin Farajpour

I want to study the role of NO synthesis inhibitors in migraine headache via meta-analysis articles in this field.

Why such difference in Heterogeneity when comparing standard mean difference vs mean difference ?

Asked 17 April 2018

David Benavides-Zora

I am doing a Sistematic review and meta-analysis of interventional techniques in headaches.

I am using revman and when calculating the effect size of the meta-analysis the MD vs SMD, the I2 drops from 95% to 50%. I wonder why? I am inclined to use MD despide its bigger heterogeneity because all studies use the same Pain scale (VAS), right ?

Are there any techniques I can use that would allow me to possibly cross over control data from one study to another?

Asked 1 September 2020

Raghav Bhargava

I am conducting a meta-analysis but some studies don't have a control group. I am meta-analyzing studies that research the effect of chemotherapy on IQ.

What software or online platform do you often use to gather research when building a literature review?

Asked 26 July 2023

Samuel Comeau

Free software to gather a tremendous amount of research material.

Should you report quality of individual studies in rapid or systematic reviews?

Asked 13 October 2020

David Jonathan Watson

I am sure that I have read guidance that reporting individual quality of studies in reviews is not good practice, but that it is better to report quality of evidence statements (which are based on more than one study). I wonder what others opinions are on this? Note: i am talking about the quality of studies included in a review not the review itself.

Sys/meta on cardiology

Asked 10 November 2023

Imane El Amri

looking for researchers that are willing to work on discussion part and risk of bias of a systematic review, for more details pls leave a message

What tools are available in Nvivo software for systematic literature review ?

Asked 1 December 2020

Govind Srivastava

How Nvivo can be used for word cloud or decision tree

How I can present data from systematic review?

Asked 7 December 2020

Sahar Taresh

I have written SLR and I would like to present the data by smart way( chart-graphic- etc)

Do you have any idea ?

Olfactory Aromatherapy vs COVID-19: A Systematic Review

Chapter

Feb 2022

Systematic Review of the Effectiveness of Aromatherapy in Labor

Article

Full-text available

Mar 2021

Aromatherapy Interventions in Elderly Person: A Systematic Review

Article

Full-text available

Jan 2020

Got a technical question?

Get high-quality answers from experts.